SRDX (Surmodics) EPS (Basic): $-1.23 (TTM As of Jun. 2025)


SRDX Surmodics Inc SRDX
51 GF Score
Price $42.98
GF Value $32.10
! 5 Warning Signs
View Full Analysis

What is Surmodics EPS (Basic)?

Surmodics SRDX -0.01% 51 EPS (Basic) is $-1.23 as of Jun. 2025. GuruFocus rates SRDX with a GF Score™ of 51/100 and a GF Value™ of $32.10. The stock has 5 warning signs investors should review.

Surmodics's basic earnings per share (Basic EPS) for the three months ended in Jun. 2025 was $-0.37. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2025 was $-1.23.

Surmodics's EPS (Diluted) for the three months ended in Jun. 2025 was $-0.37. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was $-1.23.

Surmodics's EPS without NRI for the three months ended in Jun. 2025 was $-0.38. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2025 was -0.68.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Surmodics's highest 3-Year average EPS without NRI Growth Rate was 93.30% per year. The lowest was -36.60% per year. And the median was 11.90% per year.

Surmodics  (NAS:SRDX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Surmodics EPS (Basic) Related Terms

Surmodics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Surmodics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surmodics EPS (Basic) Chart

Surmodics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.31 -1.96 -0.11 -0.82

Surmodics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.53 -0.24 -0.26 -0.36 -0.37
SRDX
51GF Score
Surmodics Inc SRDX
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Surmodics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Surmodics's Basic EPS for the fiscal year that ended in Sep. 2024 is calculated as

Basic EPS (A: Sep. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-11.542-0)/14.153
=-0.82

Surmodics's Basic EPS for the quarter that ended in Jun. 2025 is calculated as

Basic EPS (Q: Jun. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-5.318-0)/14.281
=-0.37

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-1.23 mean?
Surmodics (SRDX) has a EPS (Basic) of $-1.23 as of Jun. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Surmodics and its competitors.
Is Surmodics' EPS (Basic) too high?
Surmodics' current EPS (Basic) is $-1.23. Overall, Surmodics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Surmodics' EPS (Basic) compare to CBLL and OFIX?
Surmodics' EPS (Basic) of $-1.23 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Devices & Instruments company?
A good EPS (Basic) depends on the Medical Devices & Instruments industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Surmodics and its competitors. Surmodics's current EPS (Basic) is $-1.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surmodics stock overvalued right now?
Surmodics (SRDX) has a current EPS (Basic) of $-1.23. The stock's GF Value™ is $32.10, compared to a current price of $42.98 — trading 33.9% above its estimated fair value. The current EPS (Basic) is $-1.23. Surmodics' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Surmodics (SRDX), the current EPS (Basic) is $-1.23 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Surmodics (SRDX) Overvalued in 2026?

Based on GuruFocus' analysis, Surmodics stock appears to be overvalued. The current stock price of $42.98 is trading 33.9% above its estimated GF Value™ of $32.10.

Key valuation signals for SRDX:

  • EPS (Basic): $-1.23
  • GF Value™: $32.10 vs. price of $42.98 (33.9% above fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the SRDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Surmodics Business Description

Address 9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
51GF Score

Get the complete analysis for SRDX

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.98
Price
$32.10
GF Value